Abstract W P119: Identification of Novel Candidate Biomarkers to Define Moyamoya Disease by CSF Proteome Analysis
Purpose: Moyamoya disease (MMD) is a cerebrovascular disease characterized by progressive stenosis or occlusion of the terminal portion of internal carotid arteries. Genetic factors are closely involved in the etiology of moyamoya disease.
However, the post-genomic mechanisms are still unknown. This study was aimed to identify specific biomarkers in the cerebrospinal fluid (CSF) of patients with moyamoya disease.
Methods: This study included 6 patients with moyamoya disease and three patients with unruptured cerebral aneurysm. Their CSF was obtained from the Sylvian fissure during surgery. A comparative two-dimensional (2D) gel electrophoresis study was performed. Protein spots that showed significant differences between moyamoya patients and controls were selected for further analysis by mass spectrometry.
Results: On 2D gel electrophoresis, two proteins were upregulated and other two proteins were downregulated in the CSF of moyamoya disease. Further mass spectrometry analysis revealed that haptoglobin and alpha-1-B-glycoprotein were upregulated and apolipoprotein (Apo)-E and Apo-J were downregulated in the CSF of moyamoya disease.
Discussion and Conclusion: Upregulation of haptoglobin and alpha-1-B-glycoprotein may result from inflammatory reactions and/or angiogenesis. Downregulation of Apo-E and Apo-J may promote the cascade of endothelial apoptosis in carotid terminations. Furthermore, Apo-E is produced in the astrocytes and microglia and contributes to lipid transport to the neurons. Therefore, the downregulation of Apo-E may also be involved in the neuronal damage in moyamoya disease. The findings strongly suggest that these novel four proteins could be the candidate biomarkers to define moyamoya disease, and may shed the light on the pathogenesis of moyamoya disease, although further studies would be warranted.
Author Disclosures: D. Kashiwazaki: None.
- © 2014 by American Heart Association, Inc.